ArticleApplied biosafety : journal of the American Biological Safety Association2024
Progress and Prospects for a Nucleic Acid Screening Test Set.
Article in Applied biosafety : journal of the American Biological Safety Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The evolution of the United States nucleic acid screening policies.Frontiers in bioengineering and biotechnology · 2026Review
- Developing a standard definition for sequences of concern.Frontiers in bioengineering and biotechnology · 2026Article
- Securing the U.S. nucleic acid synthesis industry: a case for safe-harbor information sharing.Frontiers in bioengineering and biotechnology · 2026Article
- A perspective and demonstration of an approach to screening synthetic nucleic acid orders containing short nucleic acid sequences.Frontiers in bioengineering and biotechnology · 2026Article
- The Case for Limiting "Sequences of Concern" to Those with Demonstrated Pathogenic Function.Applied biosafety : journal of the American Biological Safety Association · 2025Article
- Ensuring Biosecurity and Research Agility for Outbreak Response: A Researcher's Perspective on the Federal Nucleic Acid Screening Framework.Applied biosafety : journal of the American Biological Safety Association · 2025Article
- Responsible AI in biotechnology: balancing discovery, innovation and biosecurity risks.Frontiers in bioengineering and biotechnology · 2025Review
- Why implementation gaps could undermine synthetic nucleic acid oversight.Frontiers in bioengineering and biotechnology · 2025Article
- Creating Enforceable Biosecurity Standards for Nucleic Acid Providers.Engineering biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: DNA synthesis companies screen orders to detect controlled sequences with misuse risks. Assessing screening accuracy is challenging owing to the breadth of biological risks and ambiguities in risk definitions. Here, we detail an International Gene Synthesis Consortium working group's rationale and process to develop a prototype DNA synthesis screening test dataset, aiming to establish a baseline of screening system accuracy to compare with various screening approaches. Methodology: Construction of the prototype test dataset involved four tool developers screening nucleic acid sequences from three taxonomic clusters of controlled organisms ( Results: The process highlighted several long-standing challenges in DNA synthesis screening, including the qualitative differences in approaches taken by screening tools. Our findings highlight the lack of clarity in assessing pathogen sequences with respect to regulatory control language, compounded by scientific uncertainty. We illustrate the current degree of consensus and existing challenges using classification statistics and specific examples. Conclusions and Next Steps: This prototype underscores the necessity of expert-regulator coordination in assessing gene-associated risks, offering a template for creating test sets across all taxonomic groups on international control lists. Expanding the working group would enrich dataset comprehensiveness, enabling a transition from species-focused to function-focused regulatory controls. This sets the foundation for quality control, certification, and improved risk assessment in DNA synthesis screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.